Funding for this research was provided by:
Received: 9 September 2020
Accepted: 21 January 2021
First Online: 28 January 2021
Ethics approval and consent to participate
: The study protocol was approved by the University of East Anglia Human Tissue committee and all participants gave informed consent before enrolment.
: Not applicable.
: Ewan Hunter, Matthew Salter, Aroul Ramadass, Willem Westra, Jayne Green and Alexandre Akoulitchev are employees of Oxford BioDynamics. A. Akoulitchev and A. Ramadass are company directors. Oxford BioDynamics holds patents on the EpiSwitch™ technology. The remaining authors have no conflict of interest.